Navigation Links
Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance
Date:12/10/2009

rm other promoted medicines in an antidepressant and pain market that has seen increasing use of generics and relatively modest growth overall. Cymbalta's international growth has been driven by recent approvals for depression in new markets, complemented by growth from other indications in existing markets. Plans are in place to enter the Japanese market in the near future. Cymbalta is under regulatory review for chronic pain in the U.S., and was recently approved by both Mexico and Brazil for this indication. The company expects additional international regulatory submissions in 2010.

Zyprexa continues to be the company's best-selling medicine. More than half of Zyprexa's sales now come from international markets, although U.S. Zyprexa sales still grew 4 percent in the first nine months of 2009. Zyprexa has obtained approvals for additional indications in the U.S. in 2009, and awaits final action from the FDA on Zyprexa Relprevv®, or long-acting injection. Lilly re-launched Zyprexa in Germany in early 2009 after the successful appeal of a patent decision. Share of market is stable in other EU countries and continues to grow in Japan. In other Asian nations, including China, the company expects current strong sales trend to continue.

Cialis (tadalafil) continues to demonstrate solid growth. Over the first three quarters of 2009, Cialis has grown 4 percent to $1.1 billion in sales worldwide, while the global ED market has grown only 1 percent. In the U.S., Cialis has grown 17 percent and has achieved market leadership with urologists. Internationally, Cialis is now available in more than 100 countries and is the market leader in more than 20, including 6 of the top 8 international markets. Tadalafil also has been studied for pulmonary arterial hypertension (PAH) and benign prostatic hyperplasia (BPH). The PAH indication was approved by the FDA in May and launched in August by Lilly's partner, United Therapeutics, under the brand name Ad
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
8. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
9. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
10. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
11. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Research and Markets ... Chinese Medical X-ray Film Industry Report 2014" report ... Global And Chinese Medical X-Ray Film ... on the current state of the Global medical X-ray ... The report provides a basic overview of the ...
(Date:7/11/2014)...  Kindred Hospital Houston Northwest, with Wound Care ... its new outpatient wound healing center.  The wound ... chronic, hard to heal wounds. Chronic wounds include ... lower leg wounds related to blood flow issues, ... injury wounds which are complex and demonstrate delayed ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
Breaking Medicine Technology:Global and Chinese Medical X-ray Film Industry Report 2014 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
(Date:7/13/2014)... Fuel additives are chemicals, which are ... fuel, kerosene, and so on, in order to enhance ... the corrosion effects caused by fuels and improving the ... fuel, provide economies of scale in the long run, ... cost of the fuel products. , The various fuel ...
(Date:7/13/2014)... Serena Gordon HealthDay ... A new type of sensor for people with diabetes ... using saliva instead of blood, researchers report. Scientists at ... tested it using artificial saliva. It uses light, metal and ... sugar. "Everybody knows that diabetics have to prick their ...
(Date:7/13/2014)... Recently, 2014QuinceaneraDresses.com, the distinguished special ... new range of gorgeous Quinceanera dresses . ... for elegant Quinceanera outfits is huge. Therefore, 2014QuinceaneraDresses.com ... the company’s newly released dresses are made according ... elegant and vivid. , It is worthy ...
(Date:7/13/2014)... Epidemiologists forecast an increase in the ... 8,062 diagnosed incident cases in 2013 to 11,568 diagnosed ... (AGR) of 4.35%, during the forecast period. In 2023, ... incident cases of aGVHD in the 6MM, with 4,989 ... number of diagnosed incident cases of aGVHD, with 704 ...
(Date:7/13/2014)... OH (PRWEB) July 13, 2014 Wright ... bellwether trial has been scheduled in July of 2015, ... Lipitor lawsuits are in the discovery process ... Richard M. Gergel is presiding over the multidistrict litigation ... filed on behalf of individuals who allege that they ...
Breaking Medicine News(10 mins):Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 2Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 3Health News:North America Fuel Additives Market is Expected to Reach $8,100 Million by 2017 - New Report by MicroMarket Monitor 4Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 2Health News:Saliva Test Might Someday Replace Needle Prick for Diabetics 3Health News:2014QuinceaneraDresses.com Releases Its New Quinceanera Dresses 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 2Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 3Health News:Graft-Versus-Host Disease Market (GVHD) Growing at 4.35% AGR to 2023 Says a New Report Available at ReportsnReports.com 4Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4
... EPIDEMIC ABROADMENLO PARK, Calif., May 7 Two-thirds of ... government funding to improve health in developing countries, while ... spending too much on global health, according to a ... towards U.S. global health and development assistance. Levels ...
... better than no treatment at all, study shows , , ... essential for reducing the risk of heart disease and ... matter of debate. , Now, two new analyses attempt ... attacks, all antihypertensive drugs work, with the exception of ...
... million adultsor one fourth of the people in the ... and this undiagnosed population accounts for an estimated $18 ... a study in a recent issue of Population ... Ann Liebert, Inc. ( www.liebertpub.com ). The article is ...
... of Illinois at Chicago has received nearly $1 million ... to study the benefits of green healthy housing. , ... and Reinvestment Act of 2009. , UIC researchers will ... move from distressed, unhealthy public housing into green, affordable, ...
... Results in New Compounded Medication Program GLEN BURNIE, ... largest practice-to-home delivery veterinary pharmacy today announced the ... than 1,200 pet owners from across the U.S.Key ... about having convenient services and options that help ...
... Pharma GmbH received an Orphan Drug Designation (ODD) by ... the EMEA for inhaled PARI Tobramycin 100 delivered via ... the second ODD designation that PARI Pharma has received ... first ODD was granted for PARI,s inhaled cyclosporine delivered ...
Cached Medicine News:Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 2Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 3Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 4Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 5Health News:Americans Say Maintain or Increase Funding for Global Health and Development, But Take Care of Problems at Home First in the Recession 6Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 2Health News:All Blood Pressure Drugs Lower Risk of Heart Attack and Stroke 3Health News:UIC receives $1M HUD grant to study green healthy housing 2Health News:VetCentric Releases Findings of Pet Owner Survey 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 2Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 3Health News:PARI Pharma Receives 2nd ODD From EMEA; Moves Inhaled Tobramycin - eFlow Technology Program Forward 4
... The Genesis II* Total Knee System ... Now, far more is possible with less ... options, while fully addressing both clinical and ... components meet these design goals, giving surgeons ...
Cruciate retaining, posterior stabilized and constrained components....
... The TC-PLUS Solution tricompartmental total knee prosthesis ... knee arthroplasty. State-of-the-art design and manufacturing technologies ... optimum biomechanical function as well as a ... tibial insert to keep wear to a ...
...
Medicine Products: